Microfluidx Ltd

CAR T cell therapy is a new kind of treatment for cancer and autoimmune disorders. To manufacture CAR T cell therapeutics, white blood cells are harvested from a patient's blood, genetically modified in a specialized manufacturing facility and frozen ready to be administered back to the patient. Because of immune rejection, attempts at mass-production "of...

Autologous cell and gene therapies (aCGTs) have demonstrated curative potential in several therapeutic areas, such as blood cancers. In immuno-oncology alone, it is estimated that aCGT could be relevant for up to two million patients per year by 2030, compared to only ~5,000 patients per year receiving aCGT today. Taking into account other therapeutics ar...

Public description MicrofluidX's mission is to tackle the problems of process control, scalability, and cost associated with cell bioprocessing, in particular for autologous cell therapy (CT). Its automated, closed technology allows biologists to easily carry out process development by running dozens of cell culture conditions in parallel with extreme pro...

MicrofluidX develops and manufactures a system for the production of cell and gene therapies (CGTs). CGTs are an advanced therapy which relies upon complex biological systems (cells, viruses or genetic vector systems) to perform corrective action in patients. This technology has demonstrated an unparalleled healing potential, from multiple types of cancer...